Vivorté, Inc., a vertically-integrated, specialty orthopedic biomaterials company, announced the commercial availability of a complete line of bone grafting product solutions.

Co-sponsored by: Capital One Healthcare, Kinsella Group and BioMedGPS

Cocktails and heavy hors d’oeuvres will be served at the Tommy Bahama Restaurant & Bar, just steps away from the Orange County Convention Center. The spacious patio is a perfect location for an evening of networking under the stars.

The evening will include a short panel discussion titled From the OR to the OEM: A Perspective, led by Don Urbanowicz, Principal, Urbanowicz Consulting, LLC.

India spoke loud and clear with extreme pricing caps on total knee replacements, while CMS sends mixed messages on controlling costs in the US

Outside the US the Total Joints Market softened during Q217, offsetting stable to strengthening results in US Knees and Hips, with the WW Market (as reported) growing +0.7%. Countries such as India are working to reduce the cost burden of joint replacement surgery, while in the US, the Centers for Medicaid & Medicare Services (CMS) is sending mixed messages keeping reimbursement rates relatively flat while proposing reductions to its Comprehensive Care for Joint Replacement bundled payments initiative...

Irvine, CA (PRWEB) September 12, 2017 

BioMedGPS, the leading provider of real-time analytics and strategic intelligence of the orthopedic/spine, wound care, regenerative medicine and neuro therapies markets, announces expanded coverage of SmartTRAK Business Intelligence for the European market with the addition of modules in SmartTRAK EU Extremities and EU Trauma.

FDA allowing use of historical controls may overcome a significant barrier and expedite pt enrollment in cartilage repair IDE trials notes Jack Farr, MD, at 2016 ICRS.

Injectable treatments will never turn a bad joint into a good one but may relieve pain for an undetermined period of time, concludes Elizaveta Kon, MD, in a conversation with BioMedGPS at the 2016 ICRS. Dr. Kon has performed extensive research comparing injectable technologies (e.g., PRP, HA, BMAC) and believes their primary role is in treating pain in pts who wish to avoid surgery.